Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; CELLS ; EXPRESSION ; SURVIVAL ; tumor ; TUMOR-CELLS ; BLOOD ; carcinoma ; CELL ; Germany ; THERAPY ; DISEASE ; LONG-TERM ; TUMORS ; TIME ; PATIENT ; RESPONSES ; INFECTION ; prognosis ; INDUCTION ; SKIN ; T cell ; T cells ; T-CELL ; T-CELLS ; cell culture ; culture ; IMMUNE-RESPONSES ; virus ; NO ; STAGE ; ASSAY ; LYMPHOCYTES ; HEAD ; VACCINE ; CARCINOMAS ; NECK ; squamous cell carcinoma ; immune response ; IMMUNE-RESPONSE ; vaccination ; CANCER-RESEARCH ; side effects ; head and neck ; PERIPHERAL-BLOOD ; ESTABLISHMENT ; CELL CARCINOMA ; overall survival ; CANCER STATISTICS ; ACTIVE-SPECIFIC IMMUNOTHERAPY ; IMMUNE SUPPRESSION ; MURINE MODEL ; NEWCASTLE-DISEASE-VIRUS
    Abstract: Prognosis of patients with advanced head and neck squamous cell carcinomas (HNSCC) is still poor. Therefore, we analyzed whether antitumor vaccination with a virus-modified autologous tumor cell vaccine is feasible and safe in HNSCC patients. Furthermore, we determined the influence on disease-free survival and overall survival and the vaccination-induced antitumor reactivity. In a nonrandomized pilot study, 20 patients were vaccinated postoperatively. Vaccine was prepared from the tumor cell cultures of patients by infection of the cells with Newcastle Disease Virus, followed by gamma-irradiation, and vaccine was applied up to five times. Antitumor immune reactivity was determined in the skin by delayed type hypersensitivity skin reaction and in the blood by enzyme-linked immunospot assay. Establishment of tumor cell cultures was successful in about 80% of the cases. After vaccination, we observed no severe side effects. Percentages of survival of vaccinated patients with stage III and stage IV tumors (n = 18) were 61% at 5 years. Immune monitoring revealed significant increases of antitumor delayed type hypersensitivity reactivity especially in disease-free patients, and in a significant proportion of vaccinated patients the presence of tumor-reactive T-cells in the peripheral blood even 5 to 7 years after the last vaccination. Postoperative vaccination with virus-modified autologous tumor cells seems to be feasible and safe and may improve the prognosis of HNSCC patients with advanced tumors. This could be supported by antitumor immune responses that we observed especially in long-term surviving patients
    Type of Publication: Journal article published
    PubMed ID: 15520216
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    Unknown
    German Medical Science; Düsseldorf, Köln
    In:  76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.; 20050504-20050508; Erfurt; DOC05hno207 /20050922/
    Publication Date: 2005-09-23
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1433-0458
    Keywords: Schlüsselwörter Tumorinduzierte Immunsuppression ; Zytokine ; Kopf-Hals-Tumoren ; Serumwerte ; Immunhistochemie ; Key words Tumor-induced immunosuppression ; Cytokines ; Head and neck tumor ; Immunocytochemistry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Transforming growth factor-beta (TGF-β) and interleukin 10 (Il-10) are cytokines that have a strong immunosuppressive ability. Their secretion by tumor cells is able to suppress an immunological response against tumor. Both factors have been shown to enhance tumor growth in glioblastomas and carcinoma of the breast. We determined the expression pattern of TGF-β and Il-10 in squamous cell carcinomas of the head and neck (HNSCC) and a possible association with tumor stage and their pre-treatment cytokine serum levels. Cytokine expression in primary tumors and metastases of 21 patients with HNSCC was investigated by immunohistochemistry. To assess the TGF-β2 and Il-10 levels in tumor patients before therapy 49 serum specimens were analyzed by ELISA. TGF-β2 was detected in 95% of all tumor tissues analyzed and Il-10 in 79% of all tumors. TGF-β2 was localized in tumor cells and tumor borders, while Il-10 was preferentially found in peritumoral connective tissue. Metastasizing tumors showed elevated pretreatment serum levels for TGF-β2 and Il-10. There was no correlation between TGF-β2 and Il-10 expression in tumor tissue and pretreatment serum levels. Our data show that the majority of HNSCC analyzed express TGF-β2 and Il-10. A correlation between pretherapy elevated cytokine serum levels and tumor grade was shown.
    Notes: Zusammenfassung Maligne Hirntumoren und Mammakarzinome können durch die Abgabe der Zytokine „transforming growth factor β” (TGF-β) und Interleukin 10 (Il-10) die körpereigene zelluläre Immunantwort unterdrücken. Wir untersuchten, ob TGF-β2 und Il-10 auch in Plattenepithelkarzinomen des Kopf-Hals-Bereichs nachweisbar sind und inwieweit sich die Expression im Gewebe mit dem Tumorstadium und den prätherapeutischen Serumwerten beider Zytokine korrelieren läßt. In Tumorgeweben von Patienten mit Kopf-Hals-Tumoren (n=21) wurde immunhistochemisch TGF-β2 in 95% und Il-10 in 79% nachgewiesen. TGF-β2 war vor allem in den Tumorzellen und an der Tumor-Stroma-Grenze nachweisbar, Il-10 vermehrt im peritumoralen Bindegewebe. Bei 49 Patienten wurden prätherapeutisch mittels Elisa die TGF-β2- und Il-10-Serumspiegel bestimmt. Vor allem metastasierende Tumoren zeigten präoperativ erhöhte Serumwerte. Die Zytokinexpression des Tumorgewebes zeigte keine generelle Übereinstimmung mit den prätherapeutischen Serumwerten. Wir konnten zeigen, daß die Mehrheit der untersuchten HNO-Tumoren immunsuppressive Faktoren exprimieren, und daß die prätherapeutischen Il-10- und TGF-β2-Serumspiegel mit einem fortgeschrittenen Tumorstadium einhergehen.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-1912
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...